✦ LIBER ✦

Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study

✍ Scribed by J.Tate Thigpen; John A Blessing; George Olt; Samuel S Lentz; Jeffrey Bell

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity of paclitaxel as second-line ch

✍ Sarah Lincoln M.D.; John A Blessing Ph.D.; Roger B Lee M.D.; Thomas F Rocereto M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Responsiveness of patients with advanced

✍ Kenneth D. Hatch; Jackson B. Beecham; John A. Blessing; William T. Creasman 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 2 views

A Phase II evaluation of weekly topoteca

✍ James V. Fiorica; John A. Blessing; Louis V. Puneky; Angeles Alvarez Secord; Jam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Sequential prolonged oral topotecan and

✍ Peter G. Rose; Maurie Markman; Jeffrey G. Bell; Nancy L. Fusco 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 89 KB

A phase II study of etoposide combined w

✍ Claes Tropé; Janne Kærn; Ignace Vergote; Svein Vossli 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 246 KB

Phase II trial of cisplatin as first-lin

✍ Jt Thigpen; JA Blessing; H Homesley; WT Creasman; G Sutton 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 136 KB